Correct Answer: D. PGE1
PGE1 is the primary prostaglandin responsible for maintaining ductal patency in the fetus and newborn. The ductus arteriosus is a fetal vascular shunt that allows right-to-left blood flow, bypassing the non-functional lungs. PGE1 acts on EP receptors (particularly EP2 and EP4) on ductal smooth muscle, causing vasodilation and preventing ductal closure. This mechanism is clinically exploited in neonates with duct-dependent congenital heart lesions (e.g., transposition of great arteries, critical aortic stenosis, pulmonary atresia) where PGE1 infusion (alprostadil) is the first-line emergency therapy to keep the ductus arteriosus patent and maintain systemic or pulmonary circulation. The dose used in Indian neonatal units is typically 0.05–0.1 µg/kg/min IV. Conversely, NSAIDs (which inhibit prostaglandin synthesis) are used to promote ductal closure in patent ductus arteriosus (PDA) when closure is desired. PGE1's vasodilatory effect on ductal tissue is unique among prostaglandins and is the basis for its therapeutic use in critical neonatal cardiology.
Why the other options are wrong
A. PGI2 — PGI2 (prostacyclin) is a potent systemic vasodilator and antiplatelet agent produced by endothelial cells, but it does NOT specifically maintain ductal patency. While PGI2 has vasodilatory properties, it is not the physiological mediator of ductal tone. NBE may trap students who confuse 'vasodilation' with 'ductal patency maintenance'—PGI2 is used in pulmonary hypertension, not PDA management. B. PGH2 — PGH2 (prostaglandin H2) is an unstable intermediate in prostaglandin synthesis and is not a circulating mediator. It is rapidly converted to other prostaglandins (PGE2, PGF2α, PGI2, TXA2) and has no independent physiological role in ductal regulation. This is a distractor that tests knowledge of prostaglandin biochemistry rather than clinical pharmacology. C. PGF2α — PGF2α is a potent vasoconstrictor and uterotonic agent (used in obstetrics for postpartum hemorrhage), not a ductal dilator. In fact, PGF2α causes vasoconstriction and would promote ductal closure, opposite to the desired effect. NBE pairs this with ductal patency to test whether students confuse prostaglandin types with their opposing vascular effects.
High-Yield Facts
- PGE1 (alprostadil) is the only prostaglandin that maintains ductal patency via EP2/EP4 receptor activation on ductal smooth muscle.
- Duct-dependent lesions (TGA, critical AS, PA, HLHS) require PGE1 infusion at 0.05–0.1 µg/kg/min to maintain systemic or pulmonary circulation until definitive surgery.
- NSAIDs (indomethacin, ibuprofen) promote ductal closure in PDA by inhibiting prostaglandin synthesis—opposite of PGE1 effect.
- PGF2α is a vasoconstrictor, not a vasodilator; it is used in obstetrics (postpartum hemorrhage) and promotes ductal closure, not patency.
- PGI2 (prostacyclin) is a systemic vasodilator and antiplatelet agent used in pulmonary hypertension, not ductal patency maintenance.
Mnemonics
PGE1 = Ductal Patency (E for Emergency) E1 = Emergency ductal patency. When a neonate arrives with cyanosis and duct-dependent lesion, PGE1 is the Essential first-line drug. Remember: E1 keeps the duct open (vasodilation), while NSAIDs keep it closed (inhibit PG synthesis). PGF2α = Uterine Contraction (F for Female/Fetus expulsion) PGF2α causes Female reproductive effects: uterine contraction, vasoconstriction. It does NOT dilate the ductus arteriosus. Use this to eliminate option C quickly.
NBE Trap
NBE pairs PGI2 (a well-known vasodilator) with ductal patency to trap students who confuse 'systemic vasodilation' with 'ductal-specific patency maintenance.' PGI2 is used in pulmonary hypertension, not PDA—a common confusion point in CVS pharmacology.
Clinical Pearl
In Indian neonatal ICUs, a cyanotic newborn with suspected duct-dependent lesion (e.g., transposition of great arteries) is started on PGE1 (alprostadil) infusion immediately while awaiting echocardiography and surgical consultation. Delayed recognition and failure to initiate PGE1 can result in rapid deterioration and death—this is a life-saving drug in critical neonatal cardiology.
_Reference: KD Tripathi Pharmacology Ch. 12 (Prostaglandins & NSAIDs); Harrison Ch. 281 (Congenital Heart Disease)_